Trend Aggregation Conservative ETF TACE
25.59 USD 0.00 (+0.00%)
Sep 22, 2021, 3:59 PM EDT
25.55 Day range 25.60
23.82 52-week range 25.83
- Market cap
- 16.01M
- Volume
- 5.79K
- Avg volume
- 11.09K
- Open
- 25.59
- Previous close
- 25.59
- Day's range
- 25.55 – 25.60
- 52-week range
- 23.82 – 25.83
No chart data for this range yet.
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 25.67
- 200-day average
- 25.53
About Trend Aggregation Conservative ETF
The investment seeks to provide total return. In pursuing the fund's investment objective, the fund will invest in ETFs that primarily invest in fixed income securities, real estate investment trusts ("REITs"), master limited partnerships ("MLPs"), dividend paying equity stocks including utility stocks, put options, U.S. treasuries and exchange-traded notes ("ETNs"). Fixed Income ETFs will include those that invest in domestic and foreign fixed income securities of any credit rating maturity and duration.
News
IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial 
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer 
Trend Aggregation Conservative ETF (NYSEARCA:TACE) Stock Price Down 0.2% – Time to Sell? 
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial 
Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types 
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer 
Trend Aggregation Conservative ETF (NYSEARCA:TACE) Shares Down 0.2% – Should You Sell? 
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma 
ETF Odds & Ends: 2 Closures Announced 
ETF Odds & Ends: Veterans Fund Closes
Your note
Sign in to keep a note on TACE — it syncs with the Stock Master app.